A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives.
暂无分享,去创建一个
K. Prabhash | N. Jambhekar | S. Desai | S. Desai | A. Shah | Ashish P. Shah
[1] G. Giaccone,et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.
[2] Jeffrey W. Clark,et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.
[3] T. Grogan,et al. Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] Masahiro Tsuboi,et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] W. Franklin,et al. Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment , 2010, Clinical Cancer Research.
[6] F. Cappuzzo,et al. ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC). , 2010 .
[7] A. Yoshizawa,et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.
[8] H. Mano,et al. EML4-ALK fusion in lung. , 2010, The American journal of pathology.
[9] A. Jemal,et al. The global burden of cancer: priorities for prevention , 2009, Carcinogenesis.
[10] A. Iafrate,et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.
[11] A. Sihoe,et al. The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.
[12] Y. Ishikawa,et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.
[13] E. Campo,et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.
[14] Gudrun Schleiermacher,et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.
[15] Derek Y. Chiang,et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.
[16] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[17] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[19] C. Griffin,et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. , 1999, Cancer research.